EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology.
about
Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritisBiologics registers in RA: methodological aspects, current role and future applications.Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)?Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and Registers.A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort.Relation of completeness of reporting of health research to journals' endorsement of reporting guidelines: systematic reviewTNF-α Antagonist and Infection in Rheumatoid Arthritis.Organ damage in high-risk patients with systemic and incomplete lupus syndromesDevelopment of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analysesObservational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and resultsEvolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonistsThe practical value of biologics registries in Africa and Middle East: challenges and opportunities.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Databases and registers: useful tools for research, no studies.Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.Anti-interleukin 6 receptor therapy for hyper-IgD syndrome.Infection risk after orthopedic surgery in patients with inflammatory rheumatic diseases treated with immunosuppressive drugs.The STROBE extensions: protocol for a qualitative assessment of content and a survey of endorsement.Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.Registries as real-world cohort studies that are useful and necessary in the pyramid of evidence.A Multidisciplinary Delphi Consensus-Based Checklist to Define Clinical Documentation Tools for Both Routine and Research Purposes.The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers.The landscape of comparative effectiveness research in rheumatology.Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries
P2860
Q26822912-10B50AEB-1490-4935-9301-DA4DFF46756EQ30234303-7C3BF4BB-CB8B-4792-B163-EFE12FBA2F9FQ30731527-94AC95B8-D2B9-481D-AA9D-04FBCE713AC7Q30868384-CBC71892-9E22-4730-9B79-2DE8351D6A01Q30936806-4ABC0B3D-0E49-4912-AC2E-FDEAB4B87196Q33760824-1AD3623A-A55D-425E-A347-E5BC6DD0EA3FQ33804561-D6A47D41-A4C7-412D-B528-AB81F0C8F4B1Q33872130-5F8E5324-5F4B-438A-B310-B9F42A054124Q35600608-5829EC7D-8515-4708-A177-B677224C75DCQ35605474-907F49CB-2AEB-4A40-99E0-65DC3BC2B69EQ35617617-71B45EED-682A-4B85-BFDC-9D8C3D448C32Q35617753-DB385E82-FE8D-41AA-8313-EC65CD47A651Q35621627-86F26D02-CD74-4A47-A3D8-19FFB64463BCQ36406242-37EB2589-E69C-45A4-A303-3A638200370BQ37974121-6B0D8FC4-D471-4ACC-805C-4B4036D5F30CQ38176745-FF8CB69B-6F0A-463F-984F-822C5D05071EQ38186563-75796A8D-80FC-445C-AA20-C03C640C78D7Q38533964-2AA1A84D-5B2A-4057-9DF2-7A7913402B3BQ38819214-FB6FB725-F1C3-4611-B097-AB049096D505Q40735887-C5A86F4F-9351-42C2-A230-93965EFFF98AQ43184639-7D5D08C5-72EC-4745-B0B7-C14342474921Q44964652-BAA9DCD7-A4AF-4790-BB80-3FB89385521FQ45003180-14A91302-ABB4-4ED2-9C55-51953ADD1760Q47831413-C524B7B0-85F4-462C-95E2-F20BFC5AA1FCQ48098260-9FA2E239-12B1-4D11-8C82-F237E8A287FBQ49386654-3BAD1DFA-4D6C-4CA0-A6F8-9C319CCFADCEQ51006503-5DF565EB-FAA3-4894-9CFC-6A7797F8BC3AQ53126847-5828B7FF-E903-4418-9D86-A6E8A6839B58Q56969640-6C60949A-20D8-4021-89BB-F3B97A138C61
P2860
EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
EULAR points to consider when ...... ics registers in rheumatology.
@ast
EULAR points to consider when ...... ics registers in rheumatology.
@en
type
label
EULAR points to consider when ...... ics registers in rheumatology.
@ast
EULAR points to consider when ...... ics registers in rheumatology.
@en
prefLabel
EULAR points to consider when ...... ics registers in rheumatology.
@ast
EULAR points to consider when ...... ics registers in rheumatology.
@en
P2093
P50
P356
P1476
EULAR points to consider when ...... ics registers in rheumatology.
@en
P2093
Angela Zink
Joachim Listing
Johan Askling
Paulo J Nicola
Ulrik Tarp
P304
P356
10.1136/ARD.2009.125526
P407
P577
2010-06-04T00:00:00Z